Johnson & Johnson (J&J) is a healthcare company engaged in the research, development, manufacture, and sale of a wide range of products in the healthcare field. The company serves industries such as pharmaceuticals, medical devices, and consumer health. It undertakes the research and development, and manufacture and sale of a broad range of pharmaceutical products and medical devices. The company offers its pharmaceutical prescription products through retailers, wholesalers, hospitals, and health care professionals, and medical devices to physicians, nurses, hospitals, eye care professionals, and clinics.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

J&J is focused on investing in research and development (R&D) to deliver high-quality and innovative products. The company's R&D initiatives include discovering, testing, and developing new products, improving existing products, and ensuring product efficacy and regulatory compliance before launch. The company collaborates with strategic partners to develop and commercialize drug candidates, involving activities such as R&D, marketing, selling, and distribution. Significant R&D activities include securing global rights to the NM26 bispecific antibody through the Yellow Jersey acquisition and other strategic collaborations with partners like Bayer HealthCare AG, Pharmacyclics LLC, and Legend Biotech. The R&D units of J&J are responsible for managing the company's research and development activities, which include discovering, testing, and developing new products, improving existing products, and ensuring product efficacy and regulatory compliance before launch. The unit also manages collaborations with strategic partners and handles the financial aspects of these collaborations, such as upfront, milestone, and royalty payments. It operates research facilities in the US, Brazil, China, France, Belgium, Germany, Israel, India, Poland, Singapore, Sweden, the Netherlands, Switzerland, and the UK. Some of the company’s major patents include DARZALEX (daratumumab), DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), and STELARA (ustekinumab). In FY2025, the company spent US$14,665 million on its R&D activities, which as a percentage of revenue stood at 15.6%.